TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01706406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psychoeducational intervention for female sexual arousal disorder
Description: four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief psychoeducational intervention for female sexual arousal disorder
Description: four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
Study: NCT04507295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cerebral oximetry ( INVOS 5100 )
Description: in case of critical cerebra desaturation occurred which is defined as decrease in cerebral saturation by 20% from the base line the following will be done~1. Increase FIO2 up to 100%~2. Increase PEEP up to 5 cmH2O~3. Decrease insufflation pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cerebral oximetry ( INVOS 5100 )
Description: in case of critical cerebra desaturation occurred which is defined as decrease in cerebral saturation by 20% from the base line the following will be done~1. Increase FIO2 up to 100%~2. Increase PEEP up to 5 cmH2O~3. Decrease insufflation pressure
Study: NCT01614873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo-i® ventilator, MAQUET,Critical Care, Sweden
Description: Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Servo-i® ventilator, MAQUET,Critical Care, Sweden
Description: Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
Study: NCT03411863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES at rest
Description: CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CES at rest
Description: CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES plus active hand or wrist movements
Description: CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CES plus active hand or wrist movements
Description: CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.
Study: NCT01348256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendritic cells vaccine
Description: Vaccination with autologous dendritic cells loaded with autologous tumor antigens
Study: NCT03383523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation
Study: NCT01055756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate
Description: Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate
Description: Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
Study: NCT04394403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help based on CBT principles
Description: Individuals are provided basic rationale of CBT to deal with stress, worry, anxiety, dysphoria, sleep difficulties, emotion dysregulation, and memories all related to COVID-19
Study: NCT01280643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT02730975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AA normal dose-fasting conditions (C)
Description: Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
Study: NCT00843817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: Pulmozyme® 2.5mg by inhalation
Study: NCT03542825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
Study: NCT01190254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine 5.0 mg
Description: asenapine 5.0 mg tablets for sublingual administration
Study: NCT01190254

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: asenapine-matched placebo tablets for sublingual administration
Study: NCT02376946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiPatch(TM)
Description: Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
Study: NCT01908569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MACS
Description: The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO MACS
Description: The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
Study: NCT00232908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid for 12 weeks
Study: NCT02382016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film-coated tablet 10 mg once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet once daily.
Study: NCT02412969

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Epidural
Description: control group will receive lumbar puncture epidural

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural Puncture Epidural
Description: intervention group will receive a dural puncture epidural
Study: NCT04013191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study: NCT00943228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: High dose 4gms daily
Study: NCT03292081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI
Description: PCI under OFDI guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS
Description: PCI under IVUS guidance
Study: NCT03961100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 600 mg (T1)
Description: Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 600 mg (T2)
Description: Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 200 mg (R)
Description: Reference formulation (R): entrectinib hard capsules
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study: NCT04374435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MKTP with Surgical blade
Description: In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MKTP with Negative Pressure Instrument
Description: In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
Study: NCT03542825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: Iron Sulphate 150 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chelates, Iron
Description: Amino acid chelated iron capsules contain 15 mg
Study: NCT02442739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup will be given by mouth once a week for 12 weeks.
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00363272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03248557

Intervention type: DIAGNOSTIC_TEST
Intervention: Spectral analysis of ventricular fibrillation tracings
Description: Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
Study: NCT01280643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
Study: NCT04374435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction blister grafting without cell dissociation
Description: In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
Study: NCT04189224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational Multifocal Contact Lens
Description: TEST
Study: NCT04189224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational Multifocal Contact Lens
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue® Moist Brand Multifocal Contact Lens
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue® Moist Brand Multifocal Contact Lens
Description: CONTROL
Study: NCT03800602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01280643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04220554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved support by health-care professionals
Description: Improved support to patients prescribed topical antipsoriatic drugs
Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
Study: NCT00566462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: 2 mg/d for 14 days followed by 4 mg/d for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo for for 14 days followed by 4 mg/d for 14 days
Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
Study: NCT03100591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-radiolabeled ACT-132577
Description: Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
Study: NCT04881617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexical Retrieval Training (LRT)
Description: In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Implemented Script Training for Aphasia (VISTA)
Description: In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
Study: NCT06304623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived SVF IV administration
Description: Subjects received an intravenous injection of autologous adipose-derived SVF.
Study: NCT01909089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal administration of chloroprocaine.
Description: In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~* effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~* Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally.
Study: NCT02644343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Sound
Description: Custom Sound is the programming software used to program Nucleus cochlear implants.
Study: NCT04355208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (3M™ Filtek™ Universal )
Description: universal nanofillers resin composite (3M™ Filtek™ Universal )

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (3M™ Filtek™ Universal )
Description: universal nanofillers resin composite (3M™ Filtek™ Universal )
Study: NCT03683017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse 2.0
Description: Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
Study: NCT00554814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bledilait Biofer®
Description: Bledilait Biofer® 2 mg/100 kcal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milk supplemented with ferrous sulphate
Description: Milk supplemented with ferrous sulphate (2mg/100kcal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blédilait Biofer®
Description: Blédilait Biofer® milk (1,1mg/100kcal)
Study: NCT02091102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser for the treatment of Wrinkles
Study: NCT01742832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilazodone
Description: A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
Study: NCT00617708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT01280643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT04258306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Revifast
Description: Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).